

[Polymyxin B \(injection\)](#)

Statut de médicament essentiel

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.3. Reserve group antibiotics](#)

Codes ATC: [J01XB02](#)

EMLc

Indication

Carbapenem-resistant Pseudomonas aeruginosa Code ICD11: [MG50.80](#)

INN

Polymyxin B

Type de médicament

Chemical agent

Groupes d'antibiotiques

[RESERVE](#)

Type de liste

Liste complémentaire

Formulations

Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Historique des statuts LME

Ajouté pour la première fois en 2019 ([TRS 1021](#))

Modifié en 2023 ([TRS 1049](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Wikipédia

[Polymyxin B \(injection\)](#)

DrugBank

[Polymyxin b \(Polymyxin B Sulfate\)](#)

Résumé des preuves et recommandation du comité d'experts



In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for polymyxin B on the EML and EMLc be amended to include also the equivalent strength in mg of polymyxin B base.